BRPI0616659A8 - droga terapêutica antituberculose, medicamento, e, kit para o tratamento de tuberculose - Google Patents

droga terapêutica antituberculose, medicamento, e, kit para o tratamento de tuberculose Download PDF

Info

Publication number
BRPI0616659A8
BRPI0616659A8 BRPI0616659A BRPI0616659A BRPI0616659A8 BR PI0616659 A8 BRPI0616659 A8 BR PI0616659A8 BR PI0616659 A BRPI0616659 A BR PI0616659A BR PI0616659 A BRPI0616659 A BR PI0616659A BR PI0616659 A8 BRPI0616659 A8 BR PI0616659A8
Authority
BR
Brazil
Prior art keywords
drug
tuberculosis
antituberculosis
group
drugs
Prior art date
Application number
BRPI0616659A
Other languages
English (en)
Inventor
Hashizume Hiroyuki
Matsumoto Makoto
Kawasaki Masanori
Tomishige Tatsuo
Shimokawa Yoshihiko
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37561307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0616659(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0616659A2 publication Critical patent/BRPI0616659A2/pt
Publication of BRPI0616659A8 publication Critical patent/BRPI0616659A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

droga terapêutica antituberculose, medicamento, e, kit para o tratamento de tuberculose. a presente invenção provê drogas terapêuticas antituberculose com uma potência mais alta. a presente invenção provê também drogas terapêuticas antituberculose contendo compostos de oxazol, representados pela fórmula geral (1): [em que r1 representa um átomo de hidrogênio ou um grupo alquila c1-6, n representa um inteiro de 0-6, e r2 representa a fórmula geral (a) ou os similares, em que r3 representa um grupo fenóxi (pelo menos um grupo selecionado a partir do grupo, que consiste de um átomo de halogênio, um grupo alquila c1-6 opcionalmente substituído por halogênio e um grupo alcóxi c1-6 opcionalmente substituído por halogênio que pode ser substituído no anel fenila) ou os similares, formas opticamente ativas dos mesmos ou sais dos mesmos, e drogas (ii), tais como drogas antituberculose primárias.
BRPI0616659A 2005-10-05 2006-10-04 droga terapêutica antituberculose, medicamento, e, kit para o tratamento de tuberculose BRPI0616659A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005292461 2005-10-05
JP2005-292461 2005-10-05
PCT/JP2006/320239 WO2007043542A1 (en) 2005-10-05 2006-10-04 Antituberculous composition comprising oxazole compounds

Publications (2)

Publication Number Publication Date
BRPI0616659A2 BRPI0616659A2 (pt) 2012-12-25
BRPI0616659A8 true BRPI0616659A8 (pt) 2018-05-08

Family

ID=37561307

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616659A BRPI0616659A8 (pt) 2005-10-05 2006-10-04 droga terapêutica antituberculose, medicamento, e, kit para o tratamento de tuberculose

Country Status (18)

Country Link
US (2) US8987304B2 (pt)
EP (2) EP2269694A3 (pt)
JP (2) JP5925065B2 (pt)
KR (1) KR101118942B1 (pt)
CN (2) CN101277740B (pt)
AR (1) AR056872A1 (pt)
AU (2) AU2006300320B2 (pt)
BR (1) BRPI0616659A8 (pt)
CA (2) CA2862193C (pt)
HK (1) HK1121082A1 (pt)
IL (1) IL189944A0 (pt)
PH (1) PH12015501098A1 (pt)
RU (2) RU2434632C2 (pt)
SG (1) SG165361A1 (pt)
TW (3) TW201233389A (pt)
UA (1) UA93888C2 (pt)
WO (1) WO2007043542A1 (pt)
ZA (1) ZA200802883B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196500A1 (en) * 2007-09-20 2010-08-05 Kazuo Kitakado Anhydrous dicalcium phosphate particles and production method thereof
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
EP3024445B1 (en) 2013-07-26 2019-01-09 Sanofi Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation
WO2015011162A1 (en) 2013-07-26 2015-01-29 Sanofi Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
US9822126B1 (en) 2014-10-21 2017-11-21 Council Of Scientific & Industrial Research Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof
RU2606839C1 (ru) * 2015-10-26 2017-01-10 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Лекарственный препарат противотуберкулезного действия на основе D-циклосерина в виде лиофилизата и способ получения лекарственного препарата
GB201519054D0 (en) * 2015-10-28 2015-12-09 Univ Dundee Composition
RU2627611C2 (ru) * 2015-10-30 2017-08-09 Акционерное общество "Фармасинтез" (АО "Фармасинтез") Противотуберкулезная фармацевтическая композиция, содержащая тиоацетазон
TW202227064A (zh) * 2020-09-24 2022-07-16 李建璋 使用鈣離子阻斷劑預防肺結核復發
KR102534846B1 (ko) 2021-12-14 2023-05-19 재단법인 환동해산업연구원 결핵균에 항균 활성을 가지는 해조류 추출물
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3911263A1 (de) 1989-04-07 1990-10-11 Saarstickstoff Fatol Gmbh Kombinationspraeparate
ES2095772T3 (es) 1993-05-05 1997-02-16 Palo Alto Medical Found Utilizacion de derivados de rifamicina para producir un medicamento destinado al tratamiento de la toxoplasmosis.
RU2212335C1 (ru) * 2002-07-26 2003-09-20 Беляев Дмитрий Анатольевич Композиция для гидрофобизации древесины
TWI347946B (en) * 2002-10-11 2011-09-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
EP1678185B1 (en) 2003-10-31 2008-10-08 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole compounds for the treatment of tuberculosis
TWI380975B (zh) * 2004-03-25 2013-01-01 Otsuka Pharma Co Ltd 製造胺基酚類化合物的方法

Also Published As

Publication number Publication date
EP2269694A2 (en) 2011-01-05
RU2434632C2 (ru) 2011-11-27
CA2624497A1 (en) 2007-04-19
TWI368509B (en) 2012-07-21
KR101118942B1 (ko) 2012-02-27
RU2011129167A (ru) 2013-01-20
US20150224099A1 (en) 2015-08-13
JP2012197312A (ja) 2012-10-18
BRPI0616659A2 (pt) 2012-12-25
PH12015501098A1 (en) 2015-12-07
CN101277740A (zh) 2008-10-01
IL189944A0 (en) 2008-08-07
ZA200802883B (en) 2009-09-30
RU2008117427A (ru) 2009-11-10
CA2624497C (en) 2014-11-18
JP2014132023A (ja) 2014-07-17
WO2007043542A1 (en) 2007-04-19
TW200744589A (en) 2007-12-16
JP5925065B2 (ja) 2016-05-25
TW201233389A (en) 2012-08-16
EP2269694A3 (en) 2011-03-09
AU2006300320B2 (en) 2010-08-26
AR056872A1 (es) 2007-10-31
TW201434467A (zh) 2014-09-16
RU2560676C2 (ru) 2015-08-20
KR20080052648A (ko) 2008-06-11
UA93888C2 (uk) 2011-03-25
HK1121082A1 (en) 2009-04-17
AU2010241497A1 (en) 2010-12-09
EP1931425A1 (en) 2008-06-18
CN101277740B (zh) 2012-12-05
US8987304B2 (en) 2015-03-24
CN102895230A (zh) 2013-01-30
US20090275528A1 (en) 2009-11-05
AU2006300320A1 (en) 2007-04-19
SG165361A1 (en) 2010-10-28
WO2007043542A9 (en) 2008-05-08
CA2862193A1 (en) 2007-04-19
CA2862193C (en) 2016-06-07

Similar Documents

Publication Publication Date Title
BRPI0616659A8 (pt) droga terapêutica antituberculose, medicamento, e, kit para o tratamento de tuberculose
BR112012033770A2 (pt) novo derivado de nicotinamida ou sal do mesmo
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
TW200615266A (en) Organic compounds
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
BRPI0510414A (pt) uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
UY28369A1 (es) Agentes terapéuticos
BRPI0615158A8 (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto.
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
CY1113890T1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
BRPI0510084A (pt) benzoxazina para tratamento de doenças do trato respiratório
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
BR0315580A (pt) Derivados de metileno uréia
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
DK1970372T3 (da) Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
ECSP045405A (es) Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa
BR0318533A (pt) azolidinacarbonitrilas e seu uso como inibidores de dpp-iv
BRPI0409217A (pt) derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona
ATE391710T1 (de) Substituierte azetidinverbindungen als cyclooxigenase-1-cyclooxygenase-2-inhibitoren und deren herstellung und verwendung als medikament
BRPI0418770A (pt) combinação antimicobacteriana, composição farmacêutica antimicobacteriana e processo para a preparação de uma composição farmacêutica antimicobacteriana

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/424 (2006.01), A61P 31/06 (2006.01), A61K

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]